Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with its rights issue
Mandate

Vinge has advised Oncopeptides in connection with its rights issue

March 14, 2024

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with issue proceeds of approximately SEK 300 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge, Joel Magnusson, Annie Fällström and Maximilian Bengtsson.

Related

Vinge has advised HealthCap on the establishment of HealthCap IX

 HealthCap IX has held its final closing, raising total commitments in excess of the target from a diverse investor base comprising established institutions, pension funds, and renowned investors within the life sciences sector. The strong support reflects continued confidence in HealthCap’s strategy and proven track record.
August 22, 2025

Vinge advises MAAG Gear with its MEUR 18.5 refinancing

 Vinge has advised MAAG Gear in connection with entering into a EUR 18 500 000 facility agreement with Danske Bank A/S for the purpose of, among other things, refinancing its previous credit. MAAG Gear is a leading manufacturer of industrial gear solutions for cement and mining applications with a comprehensive product portfolio and global aftermarket services offering.
August 21, 2025

Vinge has advised Direktronik in conjunction with the acquisition of Qvintus

 Direktronik, a subsidiary of Lagercrantz Group, has acquired all shares in Qvintus.
August 19, 2025